tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'CELG'

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment without Gemcitabine

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment without Gemcitabine

Written by ι Stock Market Media Group Staff — December 16, 2013

Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered – the company’s late stage clinical trials in advanced, inoperable pancreatic cancer that is.  In an editorial that accompanied the findings of an epidemiological study of patients with pancreatic cancer published in the November 20 issue of the Journal of the National Cancer Institute (JNCI), treatments using the drug gemcitabine ...

Read More →
0

FDA Approves ABRAXANE® for Pancreatic Cancer, Could Nuvilex’s Treatment Be Next

FDA Approves ABRAXANE® for Pancreatic Cancer, Could Nuvilex’s Treatment Be Next

Written by ι Stock Market Media Group Staff — September 9, 2013

After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in late January, the U.S. Food and Drug Administration (FDA) moved quickly to approve Celgene Corp.’s (NASDAQ: CELG) ABRAXANE® when used in combination with gemcitabine. Celgene announced late last Friday that the FDA has approved its supplemental new drug application of the combination as first-line treatment ...

Read More →
0

Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data

Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data

Written by ι Stock Market Media Group Staff — August 28, 2013

As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the treatment of advanced, inoperable pancreatic cancer, it looks on while one more big pharmaceutical company produces inferior data to its own.  This time it’s Incyte Corporation, a $5.5 billion market cap company that just enjoyed a more than $10 rise in its share price to ...

Read More →
0

Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation

Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation

Written by ι Stock Market Media Group Staff — August 22, 2013

While Eli Lilly’s (NYSE: LLY) cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big pharmaceutical companies are combining their own drugs with  gemcitabine in their own clinical trials in an attempt to improve upon the gemcitabine’s effectiveness when that drug is used alone for the treatment of advanced, inoperable pancreatic cancer, but they’re not finding much success.  ...

Read More →
0

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Written by ι Stock Market Media Group Staff — June 26, 2013

Nuvilex, Inc. (OTCQB: NVLX) executives aren’t daunted by the statistics.  As a matter of fact, they’re aware the research they do is directed towards attacking what the company’s Chief Operations Officer, Dr. Gerald Crabtree, calls two of cancer’s “hard targets.”  “Pancreatic cancer and brain cancers represent two such targets.  Pancreatic cancer because it doesn’t present overt symptoms until the cancer is at an advanced stage; therefore, it is more difficult to ...

Read More →
0

Nuvilex, Inc.’s Phase III Pancreatic Cancer Trials Could Address New Law’s Call for Progress

Nuvilex, Inc.’s Phase III Pancreatic Cancer Trials Could Address New Law’s Call for Progress

Written by ι Stock Market Media Group Staff — June 24, 2013

Nuvilex, Inc. (OTCQB: NVLX) has a great opportunity to demonstrate and showcase its encapsulation technology in its upcoming Phase III clinical trials for the treatment of late stage, inoperable pancreatic cancer.  There will be plenty of interested observers, and you can bet that those US Senators and Congressmen responsible for the Recalcitrant Cancer Research Act that was signed into law earlier this year, will be among them.

Nuvilex’s upcoming late stage ...

Read More →
0
Page 3 of 4 1234